These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34247436)

  • 41. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
    Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
    J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
    Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
    World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
    Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
    Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
    Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
    BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
    Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
    Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
    Peng X; Yao JY; Ma YQ; Li GH; Chen HW; Wan Y; Liang DS; Zhang M; Zhi M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1210-1216. PubMed ID: 38309492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
    Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
    Horie R; Handa O; Ando T; Ose T; Murakami T; Suzuki N; Sendo R; Imamoto E; Itoh Y
    Helicobacter; 2020 Aug; 25(4):e12698. PubMed ID: 32368846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
    Du RC; Ouyang YB; Lu NH; Hu Y
    Helicobacter; 2023 Oct; 28(5):e13012. PubMed ID: 37515414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vonoprazan-amoxicillin dual regimen with
    Dirjayanto VJ; Audrey J; Simadibrata DM
    World J Gastroenterol; 2024 Mar; 30(10):1280-1286. PubMed ID: 38596495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S; Shen W; Liu Y; Dong Q; Shi Y
    Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ; Singh TP; Wei X; Yao H; Wang HL
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
    Ratana-Amornpin S; Sanglutong L; Eiamsitrakoon T; Siramolpiwat S; Graham DY; Mahachai V
    Helicobacter; 2023 Dec; 28(6):e13019. PubMed ID: 37723133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection.
    Sereni G; Azzolini F; Camellini L; Formisano D; Decembrino F; Iori V; Tioli C; Cavina M; Di Mario F; Bedogni G; Sassatelli R
    World J Gastroenterol; 2012 Sep; 18(33):4542-8. PubMed ID: 22969227
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
    Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
    Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018.
    Pellicano R; Zagari RM; Zhang S; Saracco GM; Moss SF
    Minerva Gastroenterol Dietol; 2018 Sep; 64(3):310-321. PubMed ID: 29600697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.